SGN-35 (brentuximab vedotin)

brentuximab vedotin · Seagen Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for SGN-35 (brentuximab vedotin), covering 2014-12-18 to 2014-12-18. Get the full timeline:

Most recent: Clinical Trial Update: Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies [Phase 1]